Lucitanib

DB11845InvestigationalSmall molecule

Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor, Fibroblast growth factor receptor 2, and Fibroblast growth factor receptor 1
Curator reviewed
Formula / weight: C₂₆H₂₅N₃O₄ · 443.503 g/mol (avg)
Code names: CO-3810 · E-3810 · S-80881

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyCUDVHEFYRIWYQD-UHFFFAOYSA-NSMILESCNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1

Targets

What you can answer from here — as of June 15, 2026

9Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

30+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lucitanib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.